NuVision Biotherapies is honoured to make its inaugural appearance at the European Society of Cataract & Refractive Surgeons (ESCRS) prestigious 41st Congress, taking place in Vienna, Austria.
Our team of clinical specialists will be present at Stand C224 to discuss evidence-based, innovative approaches to ophthalmic care.
Innovations to Discover at Stand C224
Omnigen: Our proprietary dehydrated amniotic membrane offers an evidence-based solution for managing a range of ocular surface pathologies.
OmniLenz: Developed to synergistically work with Omnigen, this specialised bandage contact lens is crucial in enabling sutureless application of amniotic membrane to aid the management of moderate-to-severe dry eye disease in a non-scheduled outpatient setting.
We invite healthcare professionals, clinicians, and international partners interested in advancing patient outcomes to visit us for a comprehensive discussion at the congress.
Breakthrough Clinical Research and Efficacy
NuVision is proud our products contribute to the scientific program of the Congress, featuring multiple oral and poster presentations that showcase the clinical effectiveness of Omnigen.
- A Prospective Audit on the Use of Sutureless Human Amniotic Membrane in Ocular Surface Disease
Presenter: Mr Mohammed Elalfy, Consultant Ophthalmologist, UK
Format: Oral Presentation
Session: Ocular Surface Diseases
Room: Lehar 1-2-3 Free Paper Podium 2
Date/Time: Monday, 11 Sep, 16:30 – 18:00 CES
Key Finding: Sutureless Human Amniotic Membrane Dehydrated Matrix can effectively manage a range of ophthalmic conditions in a clinical, non-surgical setting. [For more see abstract FP22.05]
- Application of Amniotic Membrane in Dry Eye: A Clinical Assessment
Presenter: Dr Sonia Trave Huarte, Postdoctoral Researcher and Optometrist, UK
Format: Oral Presentation
Session: Dry Eye
Room: Lehar 1-2-3 Free Paper Podium 2
Date/Time: Tuesday, 12 Sep, 09:18 – 09:24 CES
Key Finding: A 1-week treatment with Amniotic Membrane (Omnigen®) applied with OmniLenz significantly alleviates symptoms and signs of moderate-to-severe dry eye disease. [For more read abstract: FP26.08]
- Clinical Outcomes of Human Amniotic Membrane-Derived Dry Matrix in Corneal Pathology
Presenter: Mr Haider Manzar, Ophthalmology Registrar, UK
Format: Poster
Key Finding: AMDDM (Omnigen®) proves effective in the clinical management of advanced corneal pathologies. [For more see abstract PO0756]
Note: For full details of the presentations, including abstracts, please visit the dedicated ESCRS 2023 online program here .
We look forward to discussing collaborative opportunities with healthcare professionals committed to improving patient outcomes in ophthalmology. Visit us at Stand C224 during the ESCRS Congress.
Disclosure: All clinical presentations declared no conflicts of interest.
About NuVision Biotherapies
Based in MediCity, Nottingham, NuVision Biotherapies is a regenerative medicine company spun out from the University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge, regenerative therapies.
About Omnigen
Omnigen Tereo processed amniotic membrane, is a patented dry preparation of human amniotic membrane. Amniotic membrane is the innermost layer of the placental sac, which protects and holds the foetus during pregnancy. NuVision upcycles and transforms this waste product of birth into an effective wound care product. The Tereo manufacturing process, developed at the University of Nottingham’s Academic Ophthalmology department, transforms this waste product of birth into a sterile and stable dry therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The product represents a unique and versatile “off-the-shelf” healing product, and it may be stored long-term. The Tereo process preserves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from ocular surface disease and conditions with unmet medical need.
Omnigen VIEW is an Omnigen product range that include central aperture windows enabling Omnigen to be applied to patients eye without covering the visual axis and impeding sight.
About OmniLenz
OmniLenz is a specially-modified bandage contact lens designed to apply and hold Omnigen at the ocular surface without the need for sutures or surgery. OmniLenz is manufactured exclusively for NuVision by Menicon, UK. Omnigen can be applied by OmniLenz using a simple 4 – 6-minute procedure in an outpatient setting. The decision to apply Omnigen to the ocular surface using OmniLenz is at the discretion of the clinician. For the first time, the healing benefits of amniotic membrane can be routinely accessed in an outpatient setting, providing healthcare professionals with a new treatment option for a broader range of ocular surface diseases.
Continue reading:
